Group 1 - KalVista Pharmaceuticals, Inc. announced the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 [1] - The offering is conducted in a private placement to qualified institutional buyers under Rule 144A of the Securities Act of 1933 [1]